The Biostatistics core serves as a resource to be called upon as needed by researchers participating in the University of Colorado Lung Cancer SPORE Grant. It offers consultation to both clinical and basic science researchers in a broad range of areas involving quantitative reasoning. This includes advice and implementation for statistical design, methodology and analysis issues, as well as epidemiological input and computing expertise. Core personnel will review all clinical protocols of the SPORE project and will write and oversee the statistical portions of these studies. The Biostatistics Core provides membership on the Protocol Review Committee of the Clinical Investigations Core for peer review of all Cancer Center and SPORE protocols. The Biostatistical core of the Lung Cancer SPORE is integrated into the Biostatistics Core of the Cancer Center. It will share its facilities, equipment and personnel to avoid duplication and for cost savings. A crucial aspect of the Lung Cancer SPORE is the evaluation of laboratory results in the clinical setting. This evaluation has clinical, statistical and epidemiologic components and implications. Examples are the prognostic importance of genetic and biological abnormalities, the sensitivity and specificity of new tests to detect dysplasia and early carcinomas, the relationships between different types of biological abnormalities, etc. The Biostatistics Core will assist in the design and evaluation of studies to ensure the scientific validity of these efforts. Where materials are gathered from national study groups, the core will work with the statistical centers of the national groups for the evaluation of biologic and clinical information. Through personnel with appointments in the Department of Preventive Medicine and Biometrics, researchers will have access, as needed, to more than 15 professionals in quantitative areas, in addition to those persons specifically assigned to the core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-03
Application #
3751701
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
DeHart, David N; Fang, Diana; Heslop, Kareem et al. (2018) Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol 148:155-162
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 435 publications